Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Assets Average (2021 - 2026)

MoonLake Immunotherapeutics' Assets Average history spans 6 years, with the latest figure at $412.4 million for Q1 2026.

  • Quarterly Assets Average fell 16.62% to $412.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $412.4 million through Mar 2026, down 16.62% year-over-year, with the annual reading at $451.2 million for FY2025, 10.17% down from the prior year.
  • Assets Average came in at $412.4 million for Q1 2026, down from $419.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $554.5 million in Q2 2024 to a low of $71.8 million in Q1 2023.
  • The 5-year median for Assets Average is $437.2 million (2025), against an average of $365.6 million.
  • Year-over-year, Assets Average tumbled 40.37% in 2023 and then soared 659.3% in 2024.
  • MoonLake Immunotherapeutics' Assets Average stood at $82.7 million in 2022, then surged by 520.64% to $513.4 million in 2023, then fell by 2.98% to $498.1 million in 2024, then fell by 15.8% to $419.4 million in 2025, then dropped by 1.66% to $412.4 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Assets Average are $412.4 million (Q1 2026), $419.4 million (Q4 2025), and $437.2 million (Q3 2025).